A new oral medication, obefazimod, demonstrated a significant 60% reduction in low-density lipoprotein (LDL) cholesterol, commonly known as ‘bad’ cholesterol, during a Phase 3 clinical trial. The drug, which targets a protein called ANGPTL3, was tested on patients with a genetic condition causing extremely high cholesterol levels and who had not responded adequately to existing treatments like statins. The trial results, published in the New England Journal of Medicine, showed the reduction was sustained over 24 weeks with a favorable safety and tolerability profile. This development offers a promising new therapeutic option for patients with hard-to-treat hypercholesterolemia, potentially reducing the risk of heart attack and stroke. Read the full article at: https://www.sciencedaily.com/releases/2026/03/260321012659.htm